Creative Planning’s MacroGenics MGNX Stock Holding History

Creative Planning’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-37,300	Closed	-$633K	–	2062
2019 Q2	$633K	Hold	37,300	–	–	﹤0.01%	954
2019 Q1	$671K	Buy	+37,300	New	+$645K	﹤0.01%	900
2016 Q4	–	Sell	-200	Closed	-$6K	–	4747
2016 Q3	$6K	Buy	+200	New	+$5.95K	﹤0.01%	3815
2016 Q1	–	Sell	-100	Closed	-$3K	–	4450
2015 Q4	$3K	Buy	+100	New	+$3.04K	﹤0.01%	3915

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Creative Planning's MGNX Position: Q3 2019 in Review

Creative Planning sold out of MacroGenics (MGNX) in Q3 2019, closing a stake of 37,300 shares — an estimated $633K sold.

Creative Planning first reported a position in MGNX in Q4 2015 and held it in 4 quarters. The position peaked at $671K in Q1 2019. 127 funds tracked by Wall St. Rank hold MGNX as of Q3 2019.

Creative Planning reported no remaining MacroGenics position as of Q3 2019 after selling out during the quarter.
Creative Planning sold 37,300 MacroGenics shares in Q3 2019, an estimated $633K.
Creative Planning first reported a position in MacroGenics in Q4 2015 and held it in 4 quarters.
Creative Planning's MacroGenics position peaked at $671K in Q1 2019.
127 funds tracked by Wall St. Rank held MacroGenics as of Q3 2019.

Based on Creative Planning's 13F filing for Q3 2019, filed 1 Nov 2019.